Abstract: Disclosed herein are compositions and methods for effecting alterations at a defined location in the genome of a non-epidermal plant cell. Further disclosed are methods for providing plants having a modified phenotype or a modified genome.

Abstract: Provided herein are methods and compositions useful for human health, e.g., for targeting one or more microorganisms resident in a host insect (e.g., arthropod, e.g., insect, e.g., pathogen vector), the modulation resulting in a decrease in the fitness of the host. The invention features a composition that includes a modulating agent (e.g., phage, peptide, small molecule, antibiotic, or combinations thereof) that can alter the host's microbiota in a manner that is detrimental to the host. By disrupting microbial levels, microbial activity, microbial metabolism, or microbial diversity, the modulating agent described herein may be used to decrease the fitness of a variety of insects that carry vector-home pathogens that cause disease in humans.

Abstract: Disclosed herein are acylated active agents and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.

Abstract: Provided herein are pharmaceutical compositions comprising Compound (I), wherein Compound (I) is of the formula: or a pharmaceutically acceptable salt, polymorph, solvate, tautomer, stereoisomer, or isotopically labeled derivative thereof. Also disclosed are polymorphs of Compound (I) and methods of using the pharmaceutical compositions and polymorphs of Compound (I) as described herein to treat a disease (e.g., cystic fibrosis, and fibrotic diseases, such as pulmonary fibrosis) comprising administering to a subject in need thereof a therapeutically effective amount of a polymorph of Compound (I) or a pharmaceutical composition comprising Compound (I) as described herein. In some aspects, the compositions are formulated for inhalation (e.g., oral or nasal inhalation).

Abstract: Provided herein are agents, compositions, and methods useful for animal health, e.g., for altering the level, activity, or metabolism of one or more microorganisms resident in a host insect (e.g., arthropod, e.g., insect, e.g., pathogen vector), the alteration resulting in a decrease in the fitness of the host. The invention features a composition that includes an agent (e.g., phage, peptide, small molecule, antibiotic, or combinations thereof) that can alter the host's microbiota in a manner that is detrimental to the host. By disrupting microbial levels, microbial activity, microbial metabolism, or microbial diversity, the agents described herein may be used to decrease the fitness of a variety of insects that carry vector-borne pathogens that cause disease in animals.

Abstract: Disclosed are conjugates including a recognition element covalently bonded to or linked through a linker to a payload. The payload is a pharmaceutical agent (e.g., an antineoplastic agent, anti-infective agent, or anti-inflammatory agent) or a diagnostic agent. Also disclosed are methods of using the conjugates.

Abstract: Provided herein are methods and compositions for modulating the fitness of a host invertebrate (e.g., insect, mollusk, or nematode) by altering interactions between the host and one or more micoorganisms resident in the host. The invention features a composition including a modulating agent (e.g., a polypeptide, nucleic acid, small molecule, or combinations thereof) that can induce changes in the host's microbiota in a manner that modulates (e.g., increases or decreases) host fitness. The modulating agent described herein may modulate the fitness of a variety of invertebrates that are important for agriculture, commerce, and/or public health.

Abstract: The present disclosure described herein provides compositions with a membrane-penetrating properties and methods for allowing translocation across a membrane without disruption.

Abstract: Therapeutic chondrisome and mitoplast compositions and related methods are described.

Abstract: Therapeutic chondrisome compositions and related methods are described.

Abstract: Disclosed herein are compositions and methods for effecting alterations at a defined location in the genome of a plant cell or plant protoplast. Further disclosed are methods using an RNA-guided nuclease to alter a target nucleotide sequence in a cell or protoplast of a plant; embodiments of such methods include treatments with chemical or physical reagents or treatment of the cell or protoplast with a specific thermal regime, such as a heat treatment.

Abstract: Disclosed herein are active agents, compositions containing them, unit dosage forms containing them, and methods of their use, e.g., for treating a metabolic disorder or nonalcoholic fatty liver disease or for modulating a metabolic marker or nonalcoholic fatty liver disease marker.

Abstract: A system for verifying medication doses in a filled medication package comprises an imaging unit to produce at least one image of a filled medication package and a verification unit for receiving the image of the filled medication package. The verification unit comprises a dose locator to determine from the image a location of any dose in the filled medication package, and associate a time period to the location. It also comprises a dose verifier to verify an identity of any dose from the visual characteristics of the image as a function of dose reference profiles. The verification unit compares an identity and time period of the doses of the filled medication package to a prescription and has an interface for producing verification output based on the comparison of the verification unit. A method for verifying medication doses in a filled medication package is also provided.

Abstract: Provided herein are methods and compositions for food and feed applications, e.g., for targeting one or more microorganisms resident in a host insect, the modulation resulting in an increase in the fitness of the host. The invention features a composition that includes a modulating agent (e.g., phage, peptide, small molecule, antibiotic, or combinations thereof) that can alter the host's microbiota in a manner that is beneficial to the host. By promoting favorable microbial levels, microbial activity, microbial metabolism, and/or microbial diversity, the modulating agent described herein may be used to increase the fitness of a variety of insects utilized in human food or animal feed industries.

Abstract: Provided herein are methods, pharmaceutical compositions, and kits for treating and/or preventing a viral infection resulting from a coronaviridae family virus in a subject in need thereof, comprising administering to the subject a compound of Formula (I), or a pharmaceutical composition comprising a compound of Formula (I). Further provided herein are methods for inhibiting the viral entry into a cell of a coronaviridae family virus (e.g., alpha-coronavirus (e.g., HCoV-NL63, HCoV-229E), betacoronavirus (e.g., SARS-CoV, SARS-CoV-2, MERS-CoV, HCoV-OC43, HCoV-HKU1)) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of Formula (I) as described herein.

Abstract: The present disclosure provides compositions with a modulating gene expression and methods for modulating transcription.

Abstract: In some aspects, fusosome compositions and methods are described herein that comprise membrane enclosed preparations, comprising a fusogen. In some embodiments, the fusosome can the target cell, thereby delivering complex biologic agents to the target cell cytoplasm.

Abstract: Provided herein are methods of treating a viral infection in a subject in need thereof, comprising administering to the subject a compound of Formula (I), or a pharmaceutical composition comprising Formula (I). Further provided herein are methods for inhibiting the replication of a virus (e.g., a togaviridae family virus (e.g., an alphavirus (e.g., Chikungunya virus, Eastern equine encephalitis, Mayaro virus, Venezuelan equine encephalitis virus, Western equine encephalitis)), a filoviradae family virus (e.g., a Marburg virus (e.g., Marburg virus, Ravn virus)), human respiratory syncytial virus (i.e., human orthopneumo virus), a flavivirus (e.g., dengue virus, Usutu virus, Japanese encephalitis virus, Powassan virus, yellow fever), a paramyxoviridae family virus (e.g., an orthoparamyxovirinae virus (e.g., a henipavims (e.g., Nipah virus), a morbillivims (e.g., measles morbillivirus))) in a subject in need thereof.

Abstract: Disclosed herein are compositions and methods for increasing the fitness of insects for agriculture or commerce, wherein the composition includes a postbiotic agent (e.g., a short chain fatty acid).

Abstract: This invention relates generally to viral vectors and viral particles based on Anelloviruses, which can be used to deliver an agent (e.g., an exogenous effector or an endogenous effector, e.g., a therapeutic effector) to a cell (e.g., a cell in a subject to be treated therapeutically). Described herein are anellosomes, anellovectors, and compositions and uses thereof.